As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody Tecentriq (atezolizumab) for a specific type of previously untreated metastatic bladder cancer.
https://www.pharmalive.com/wp-content/uploads/2021/04/Genentechs-Tecentriq-Survives-FDA-Accelerated-Approval-Vote-in-mTNBC-BioSpace-4-28-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-29 10:51:552022-11-29 12:32:54Roche withdraws Tecentriq for bladder cancer indication